Approval · Notice of Compliance 30522 · 2023
TAPAZOLE: Notice of Compliance 30522
Issued April 14, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30522
- Date
- April 14, 2023
- Company
- Paladin Labs Inc
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph. Correct the drug product manufacturing standard claim. Deletion of 20 mg strength following a DIN cancellation. Update to labels to align with Plain Language Labelling regulations
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TAPAZOLE | Not yet assigned | — |
Medicinal ingredients
- METHIMAZOLE 5 MG per TAB
- METHIMAZOLE 10 MG per TAB